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Abstract
The South-East Asia Region contains an estimated 400,000-500,000
people who inject drugs (PWID). HIV prevalence among PWID is com-
monly 20% or higher in Indonesia, Thailand, Myanmar and some
regions of India. Opioid substitution therapy (OST) is an important
HIV prevention intervention in this part of the world. However, key
challenges and barriers to scale up of OST exist, including: pervasive
stigma and discrimination towards PWID; criminalisation of drug use
overshadowing a public health response; lack of political will and
national commitment; low financial investment; focus towards tradi-
tional treatment models of detoxification and rehabilitation; inade-
quate dosing of OST; and poor monitoring and evaluation of pro-
grammes. Our review of local evidence highlights that OST can be suc-
cessful within the Asian context. Such evidence should be utilised
more widely to advocate for policy change and increased political com-
mitment to ensure OST reaches substantially more drug users. 
Background
Global estimates indicate that there are 15.9 million (range 11.0-
21.2 million) people who inject drugs (PWID) across 151 countries.1,2
Of these, approximately three million (range 0.8-6 million) PWID are
HIV infected.1 Furthermore, it is estimated that 10 per cent of all new
HIV infections can be attributed to injecting drugs, rising to 30 per
cent when sub-Saharan Africa is excluded.3 Within what the World
Health Organization (WHO) define as their South-East Asia Region
(SEAR) there are an estimated 400,000-500,000 PWID,4 primarily
located in countries that experience a high or medium burden of illic-
it drug injecting (WHO Office for SEAR covers 11 countries:
Bangladesh, Bhutan, DPR Korea, India, Indonesia, Maldives,
Myanmar, Nepal, Sri Lanka, Thailand and Timor-Leste). 
Data from several sources show that high risk behaviours among
PWID are common and provision of comprehensive HIV prevention
services varies (Table 1). HIV prevalence among PWID in South-East
Asia was commonly identified at 20-25% and has remained consistent-
ly high in Indonesia, Nepal, Thailand, Myanmar and some regions of
India.5 Whilst a decline was recorded in HIV prevalence among
Nepalese PWID, from 68% in 2002 to 21% in 2009 and 6% in 2011,6-8
HIV prevalence rose in Bangladeshi PWID, from 4% in 2003-2004 to 7%
in 2007,9 and in Punjab (India) from 13% in 2006 to 21% in 2011.10
High-risk behaviours among PWID, such as the sharing of contaminat-
ed needles and syringes, remain a major determining factor in the
course of the HIV epidemic throughout Asia.11-13
The ongoing HIV epidemic among PWID in South-East Asia has
prompted many countries to develop HIV policies linked to national
HIV strategic plans in which harm reduction interventions are
increasingly viewed with understanding and acceptance.4 UNAIDS
UNDOC and WHO outline nine interventions as part of a comprehen-
sive package that has the greatest impact on HIV prevention, treat-
ment and care for PWID.14 Meta-analysis and systematic reviews
show conclusively that providing opioid substitution therapy (OST)
together with needle and syringe programmes and antiretroviral
treatment targeted towards PWID have the greatest effect in prevent-
ing HIV infection.15
In this article the focus is upon one essential harm reduction inter-
vention, OST, and its use in countries that fall under the administra-
tive purview of WHO’s SEAR, with specific focus on Bangladesh, India,
Indonesia, Maldives, Myanmar, Nepal and Thailand. We excluded
Timor-Leste, Bhutan and the Democratic People’s Republic of Korea
due to limited data.  
Methadone has been prescribed for the treatment of opioid depend-
ency for over four decades and buprenorphine has been available since
the early 2000s. Both were added to the WHO list of essential medi-
cines in 2005, and are usually consumed orally or sublingually as main-
tenance treatment to relieve opioid withdrawal and to reduce cravings.
Research has shown them to be effective in the reduction of HIV risk
behaviours and other comorbidities.16,17 Due to the chronic nature of
opioid dependency, treatment outcomes are better in long-term thera-
py incorporating adequate dosing (at least 60 mg of methadone and 8-
6 mg buprenorphine per day).16
Despite the strong evidence for various benefits resulting from the
use of OST – improved retention in treatment for HIV, HCV and opioid
use,16 reduced illicit opioid use,17 reduced risk of HIV,18 reduced crim-
inality, better psychosocial outcomes and decreased risk to pregnant
drug-dependent women19 (during the intra-uterine, partum and post-
partum period20) fewer than three per cent of PWID in the South-East
Asia Region have access to OST.12 In this article we explore the histor-
Significance for public health
Several countries in the World Health Organization South-East Asia Region
can be commended for introducing opioid substitution therapy (OST) to
address the ongoing HIV epidemic among people who inject drugs (PWID).
Local evidence shows OST is an effective drug treatment approach in the
Asian context given sufficient technical and institutional support. However,
despite much progress, the number of OST dispensing sites and recipients
remains totally inadequate in terms of impact upon the current HIV epidem-
ic among PWID. Ongoing advocacy is needed if countries are to achieve the
WHO’s target of 40% of PWID being dosed with OST. Greater political com-
mitment a strengthened policy environment, capacity building for OST clin-
ics, lessening the criminalisation of drug use and promoting a public health
response will give many more PWID access to OST and slow the advance of
the HIV epidemic. 
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ical adoption of OST, the current situation, some of the major chal-
lenges, and suggest ways to scale up OST in the SEAR.
Methods
We reviewed published and grey literature located using Medline
and PubMed, WHO program documents for the countries of the SEAR,
the Joint United Nations Programme on HIV/AIDS (UNAIDS), the
United Nations Office on Drugs and Crime (UNODC) documents, and
generic internet search engines between October 2011 and June 2013.
Direct email requests were made to WHO HIV country focal points and
official government counterparts for additional data and comments
about OST in the SEAR between September 2010 and March 2013.
ResultsImplementation of opioid substitution therapy
The amount and quality of the data available on the commencement
of OST programmes, responsible agencies, the number of PWID receiv-
ing OST, and the linkages with other health and non-health systems
vary considerably among the countries in South-East Asia (Table 2). 
Nepal started a government-approved methadone-based OST pro-
gramme in 1994.21 Despite satisfactory outcomes, the programme was
suspended in 1998, and then restarted as an emergency response for
HIV prevention in September 2007.4 In India, sublingual buprenorphine
treatment commenced in 1993 as a pilot project and has been licensed
for treatment of opioid dependence in drug treatment centres since
1999.22,23 Methadone maintenance therapy (MMT) commenced in
India in 2011.24
In Thailand, limited methadone treatment became available in 1979,
primarily as a detoxification program in approved clinics. In 1989 a
national clinical trial of MMT was initiated. MMT started in Bangkok as
an HIV prevention measure in 1990, and gradually extended to a few
clinics outside the capital.25,26 Buprenorphine was approved for opioid
treatment in 2007, and a trial of buprenorphine-naloxone was initiated
in Chiang Mai during the same year, but it is not routinely used in opi-
oid treatment programs.26
Buprenorphine was introduced in Indonesia in 2001, and the manu-
facturers of the drug encouraged private practitioners to prescribe the
medication to drug-dependent clients.27,28 In 2003 the Indonesian
Ministry of Health established MMT (with technical and financial
assistance from WHO) in two pilot projects, one in Jakarta and one in
a joint pilot within a Bali prison and a hospital. These two pilots con-
tinued until the end of 2005, serving a population of approximately 300
drug users.29
Preparation for the introduction of methadone began in Myanmar in
2004, with the Ministry of Health commencing the delivery of MMT
over February and March 2006 in four drug treatment centres. Around
2900 clients were receiving MMT by 2013.30
In November 2008, MMT was introduced into the Maldives as part of
a pilot study;31 buprenorphine remained unavailable due to its classifi-
cation as an illegal substance.4Opioid substitution therapy availability in 2009-2012
In Nepal, as of June 2011, 380 clients were receiving methadone
from three sites in the cities of Kathmandu, Patan and Pokhara
(Kramarz P., 2011; personal communication). The demand for
methadone was reported to be high, with a long waiting list to join the
programme. In Pokhara, 88 PWID were enrolled to receive methadone
and 62 were active recipients.32 In 2009, 30 Nepalese PWID received
buprenorphine administered as part of a three-month tapering reduc-
tion dose rather than long-term maintenance therapy.12 At the end of
2010, NGOs were dispensing buprenorphine from six sites to 175
clients. The three-month duration of treatment of 2-4 mg per day
remained unchanged. Take-home/home delivery of buprenorphine was
only granted under exceptional circumstances (Pandey B., 2010; per-
sonal communication). The provision of buprenorphine is not current-
ly an official part of the government OST programme.  
Initial Indian targets were for 40,000 PWID to receive OST by 2012,
with delivery through 320 sites, primarily NGOs or government-run
treatment centres.4 By May 2011, buprenorphine was available from 52
sites and 4810 clients were in treatment; data from December 2012
show that 120 buprenorphine sites were delivering treatment to 7500
regular patients (in India regular patients are defined as those access-
ing OST 24 days or more per month; those that received less frequent
treatment are not included).30
Apart from small pilot studies Methadone has not been available for
clinical use in India following its removal from the Indian pharma-
copoeia in 1982.33 However, in early 2010 the government approved the
use of methadone in a pilot study intended to involve six sites in late
2010. By 2012 four methadone dispensing sites were servicing 350
patients (Kumar R. 2013; personal communication). A buprenorphine
project commenced inside Tihar prison, New Delhi in late 2008, but
client numbers remain small. 
In 2009 the Bangkok Metropolitan Administration funded 20
methadone clinics at two hospitals and 18 health centres,34 and across
Thailand an estimated 4000-5000 patients were receiving methadone.12
In 2010, 2200 patients received methadone treatment, but probable
duplication of some client records makes this number uncertain, and
whether they were receiving long-term treatment is undetermined
(Thanpresertsuk S., 2011; personal communication). The reasons for
the apparent fall in client numbers between 2009 and 2010 are
unknown (the 2009 figures are estimates only), although the general
shift from opioid use to stimulant use in Thailand is likely to have con-
tributed. In 2012, 147 sites were dispensing methadone to 2777
patients.30 Methadone is the National Health Security Office’s approved
OST medication and was placed on the Thai Essential Drug List in
2008; it is available as part of the Universal Health Coverage package
for all Thai citizens. In 2009, an estimated 150 clients were reported to
be receiving buprenorphine as part of an HIV prevention trial at Chiang
Mai University, which has since been completed.4,12
In Indonesia, methadone expansion began in 2006 with seven clin-
ics serving 1000 clients by the end of that year.29 By April 2010
methadone was available in ten provinces from 51 clinics (five special-
ist hospitals; 10 general hospitals; 30 primary health centres; and six
prison and detention centres) (Sarasvita R., 2010; personal communi-
cation). In June 2011, Indonesia had 68 government-funded clinics
with 2540 active patients. In addition, more than 50 medical pre-
scribers in private practices were dispensing buprenorphine to an esti-
mated 3000 patients.35
In Myanmar in January 2010, 821 patients were receiving
methadone from eight sites in four states,3 and by June 2011 patient
numbers had increased to 1087.36 In late 2012, 13 methadone sites
were dispensing to 2909 patients.30,37 Methadone was dispensed from
drug treatment centres as part of Global Fund Round.9
In the Maldives, 47 patients had been enrolled to receive methadone
in late 2009,4 but by April 2010 only 17 patients remained, decreasing
to 11 by August 2010 (Mohamed A.J., 2010; personal communication);
by July 2011 patient numbers had rebounded to 57 (Aminath Z., 2011;
personal communication). Barriers to methadone programme enrol-
ment in the Maldives include the need to obtain clearance from five dif-
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Table 1. HIV prevalence among people who inject drugs in selected South-East Asia Region countries: interventions, behaviours and reach of
HIV prevention programmes 2009-2012.
Country Estimated  Estimated HIV Harm PWID report using PWID reporting PWID reached with 
number prevalence reduction sterile injecting use of HIV 
of PWID (%) interventions equipment last time condoms last prevention 
adopted as policy of injecting (%) having sexual programmes (%)
for PWID (n.) intercourse (%)  
Bangladesh 21,800-23,800 7 Dhaka 9 33.6 (male) 30.2 2.1
73.8 (female)
India 177,000-180,000 7 9 29-88 44-100 10-83
Indonesia 105,784 36 9 88.3 35.7 43.38
(73,663-201,131)
Maldives 793 (690-896) 0 6 69-77  6 Not available
Myanmar 75,000 22 9 81 (last month) 78 8274
Nepal 17,000-24,000 6 Kathmandu 8 50.8 99 56.9
Thailand 40,300 22 9 <50 <40 Not available
Source: WHO, UNAIDS, UNODC, UNGASS reports and Harm Reduction International (Global State of Harm Reduction Towards An Integrated Response 2012). PWID, people who inject drugs.
Table 2. Opioid substitution therapy in selected South-East Asia Region countries: start date, numbers, linkages, compulsory/court
mandated, modality.
Country Year first Key responsible No. OST No. receiving OST service OST service Compulsory or Modality of
trialled, agencies sites OST links with other has links with court mandated OST
started for OST (2010-2012) (2009-2012) health services non-health treatment delivery
OST services exists
Bangladesh 2010 - M ICDDR,B with 2 - M 188 Based in govt detox No - but plans No Government
funding support clinic, where several underway
from UNODC psychiatrists provide
support as and when
needed. The OST
clinic is also linked to
ICDDR, B voluntary
counseling testing unit
India 1993 - B MoH, Ministry of 120 - B 7500 - B Weak to good links Weak to good links No Government
2011 - M Social Justice, 4 - M 350 - M & NGO
Empowerment,
& National AIDS
Control Office
Indonesia 2001 - B MoH for methadone. 68 - M 2540 - M Weak links Weak Links No Government
2003 - M Private practitioners ? - B 3000 B & Private
dispense (50 doctors
buprenorphine trained in
following training buprenorphine
Largely dispensing
unsupervised by Moh
Maldives 2008 - M Moh 1 - M 57 - M No No No Government
Myanmar 2004 - M Department of 13 - M 1637 - M Weak to good links Weak to good links Yes Government
Health - medical
care 
Nepal 1994 - M Ministry of Home 3 - M 386 - M Overall weak links Overall weak links No Government 
Affairs, UNODC, 175 - B but some sites have but some sites & NGO
Hospitals, NGOs good links but with have good links
(not part of official constraints
government programs)
Thailand 1979 - M Thanyarak Institute 147 - M 1183 - M Fully integrated Weak links Yes Regional drug 
2007 - B of the Department ? - B ? - B (most OST services treatment 
of Medical Services, attached within health centers (of the 
under the Ministry care settings) Department of
of Public Health Medical
Services) &
Govt Hospitals
OST, opioid substitution therapy; B, Buprenorphine; M, Methadone; ICDDR,B, International Centre for Diarrhoeal Disease Research, Bangladesh; MoH, Ministry of Health.
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ferent government departments to ensure no criminal cases are pend-
ing. It is reported that the methadone programme functions well, but
scope for improvement remains.38
In July 2010, after several years of advocacy to initiate OST,
Bangladesh commence methadone provision, starting with one site in
Dhaka. By early 2013 an additional site had opened and 188 clients
were receiving methadone (Azim T., 2013; personal communication).Challenges and barriers to scale up of opioidsubstitution therapy
Various common challenges and barriers exist to the implementa-
tion and expansion of OST services. Throughout the region drug users
continue to experience high levels of stigma and discrimination due to
their substance use. This impacts upon the delivery of general health
services, including access to OST.39-41 In the UK it has been noted that
key government policies to assist PWID reintegration and recovery
through the use of OST were highly unlikely to succeed while stigma-
tising attitudes towards PWID remain pervasive.42 Stigma and discrim-
ination remain major barriers across South-east Asia. 
Acknowledging drug use and responding to HIV risk-taking behav-
iour was largely delayed across Asia in comparison to many Western
countries,43,44 and the criminalisation of drug use still commonly over-
shadows a public health response to address this problem.45 Various
countries in the SEAR force drug users into compulsory drug detention
centres. Official reports state that 235,000 people were detained in over
1000 compulsory drug detention centres in East and South East Asia
alone in 2012. Since 2012, many United Nation agencies have called for
their closure for reasons including human rights abuses and a lack of
evidence of their effectiveness.46 As found in other regions of the
world, the attitude that the abstinence model of drug treatment is of
paramount importance persists and rejection of the concept of OST
maintenance is widespread, despite opioid dependence being acknowl-
edged as a chronic medical condition.47 As a result, it could be argued
that this has been the major reason for reduced political will, financial
under-investment and lack of commitment toward the scaling up of
essential harm reduction interventions, including OST. 
Advocacy for and funding of OST scale-up in the countries under
review remains largely driven by UN agencies and the international
donor community. Initial funding of and sustainable investment in
harm reduction services, including OST, remains a perennial problem.
Recent global studies have revealed over 90% of HIV-related harm
reduction funds in low and middle income countries stem from inter-
national donors, and total funding remains inadequate.44 The cost of
OST for individual recipients is prohibitive in many cases, and this
greatly reduces the numbers of PWID in treatment. In Indonesia, while
methadone could cost a client 1-2 UD Dollars ($) per dose through a
government service, an 8-12 mg dose of buprenorphine commonly costs
11-17 $ through a private medical practitioner. As a result, many PWID
can only afford to purchase an inadequate dose that proves ineffective
and contributes towards ongoing injecting of illicit drugs.
Despite these problems, it is important to highlight progressive
steps from Asian countries such as Malaysia and China, where govern-
ments strongly endorse OST and are expanding the OST programme
nationwide. By 2009, China had 680 methadone clinics in 27 provinces
with 242,000 patients (ever) enrolled, while Malaysia had 59 govern-
ment facilities and nine private clinics dispensing methadone to 7065
registered clients, with an additional 10,000 clients receiving
methadone through private practitioners.39,48 In 2011 Malaysia further
expanded its methadone programme, with substantially more distribu-
tion sites: 168 public health clinics, 48 public hospitals, 24 general prac-
titioners (GPs), 32 National Anti-Drug Agency sites, 18 prisons and two
others. A cumulative 20,955 PWID have been registered in public facil-
ities since 2006 and another 23,573 PWIDs are receiving MMT from
GPs. Due to the separate registration systems of private and public
services, it is not possible to identify whether patients receiving
methadone from private GPs were also registered with public facilities
(Naning H., 2012; personal communication).
In all countries under review, the focus remains largely on the tradi-
tional treatment model of detoxification and rehabilitation despite
strong evidence of recidivism, with rates often ranging from 60-
100%.13,48 Despite the international evidence highlighting the broad-
ranging health, social and economic benefits of OST,49 a lack of in-
depth knowledge, awareness and education about OST among policy-
makers, community members, drug users and the health sector con-
strains the scaling up of OST.31,50,51 As found worldwide, one of the
greatest obstacles to OST acceptance in the SEAR is limited acceptance
and practice of evidence-based medicine associated with OST in the
medical workforce.47
Research has shown that it is commonly perceived that providing OST
is simply replacing one drug with another, despite evidence that
methadone is superior to non-pharmacological methods in terms of
client retention in treatment, reduced self-reported heroin use and both
urine and hair analysis.52,53 In some parts of the world, including in some
Asian countries, providing OST can be viewed as a failure to deal with
the criminal behaviour of drug users. Consequently, the implementation
of an abstinence-based model of treatment is still strongly advocated as
the primary approach to address drug dependency. In addition, tensions
continue between supply/demand reduction and harm reduction
approaches, and impacts upon expansion of OST services.54
Highlighting an effective OST treatment model that builds upon local
evidence can contribute towards expansion of drug treatment services
for PWID. One aspect of effectiveness is to achieve an optimal dose of
OST (usually greater than 60 mg of methadone) that can lead to a
decrease in the use of illicit drugs and ensure a higher retention rate
and decrease in HIV risk behaviours.55 However, it is not uncommon
practice for a lower dose to be prescribed for clients receiving OST in
South-East Asia. For example, in Indonesia an integrated biological
survey among PWID noted that most of those who received methadone
in the past year were still injecting illicit opioids in the past week, and
it was speculated that one reason for this was inadequate dosage.56
Doses of methadone of more than 60 mg daily are recommended,
with most clients requiring 60-120 mg daily.57 In some countries under
review, low-dose buprenorphine was common practice (<4 mg daily).
Recent buprenorphine guidelines in India (2009) recommend 4-8 mg
as the optimal buprenorphine dose,32 despite international evidence
recommending that people be stabilised on 8-16 mg daily.57 Overall poor
monitoring and evaluation of OST programmes exists in the countries
under review and this does not allow local experiences to be translated
into coherently managed knowledge about a program. As a conse-
quence this impacts upon seeking ways to improve and expand cover-
age of the OST service.  
DiscussionMoving forward with scale-up of opioid substitutiontherapy
In 2005, WHO added methadone and buprenorphine to the WHO
Model List of Essential Medicines, and this endorsement  provided
high-level official support to advocate with the appropriate government
ministries for the introduction and wider use of OST in treatment pro-
grammes. However, despite the official use of OST in all countries
under review, specific policies for OST either do not exist or are too
underdeveloped to have the desired impact. Many countries in the
region need greater official acknowledgement of PWID and the role
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they play in the HIV epidemic and respond according to the epidemio-
logical and national context.58,59
A national policy would assist in establishing a set of standards for
OST provision and address the needs of politicians, health administra-
tors, program managers, clinicians and OST recipients. Such policies
should reflect a national agreement about the important strategic role of
OST in reducing the adverse health, social and economic consequences
of drug use, and outline key objectives and procedures. Evidence of the
benefits of OST in all countries under review warrants increased high-
level support for and expansion of OST, as has occurred in China.39
Criminalisation of drug use continues to restrict the wider utilisa-
tion of OST. As a result it is critically important to increase the law
enforcement sector’s understanding of OST, and to advocate for it to
endorse the expansion of OST. National Working Groups or Task Forces
on harm reduction, with a high priority on OST, are similarly important,
requiring participation of senior officials from health, police, academia
and representatives of civil society for maximum benefit. 
Despite an incremental growth in knowledge of OST since its intro-
duction in various countries of South-East Asia, building staff and
institutional capacity remains critically important.  The skills and
knowledge of staff working on drug dependency and OST is often lack-
ing, and consequently regular training programmes are necessary.
Poly-drug use is widespread, with opioids often being mixed with ben-
zodiazapines and other pharmaceuticals; many clinical staff are uncer-
tain as to how to address these issues. Training programmes facilitate
sustainable expansion and improved quality of OST services, and
encourage long-term commitment towards OST treatment patients and
PWID in general. Of equal importance is the need to conduct regular
monitoring and evaluation of OST programmes at national and local
level. Data identifying both effective approaches and difficulties inform
policymakers and other stakeholders about how to improve quality and
continue expansion of OST services.    
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